Vanda Pharmaceuticals (VNDA) PT Raised to $24 at Brean Capital Following Fanapt Ruling

Brean Capital analyst Difei Yang reiterated a Buy rating and raised his price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $24.00 (from $20.00).

This follows the favorable ruling on the '610 patent, which prevents the FDA approving ANDA to Fanapt until November, 2027 which is a major improvement from our previous assumption of generic entry in 2023.

For an analyst ratings summary and ratings history on Vanda Pharmaceuticals click here. For more ratings news on Vanda Pharmaceuticals click here.

Shares of Vanda Pharmaceuticals closed at $14.17 yesterday.

You May Also Be Interested In

• Boston Scientific (BSX) PT Raised to $83 at Stifel
• Prudential Financial (PRU) PT Raised to $116 at Evercore ISI
• Compass Minerals International (CMP) PT Lowered to $15 at Deutsche Bank